Your results for

Filter by

Filter by
Results

Filter by

Content type
Key content topics
Key audience
Top cancer treatments

Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016

08/02/2021
/ Publications
/
IMPT

Based on the SEER database, this study reported that for Medicare beneficiaries with a first-time diagnosis of prostate cancer, the utilization of IMRT, proton...

MRI-based IMPT planning for prostate cancer.

11/11/2019
/ Publications
/
IMPT

Published in the Green Journal, this study led by MGH aimed to quantify the clinical applicability of converted MR images as a substitute of CT for IMPT...

Toxicity and Survival After IMPT Versus Passive Scattering PT for NSCLC.

10/10/2020
/ Publications
/
Toxicity
IMPT

This MD Anderson study compared toxicity profiles and clinical outcomes after IMPT versus PSPT for 139 patients with locally advanced NSCLC. Compared to the...

Proton Therapy in NSCLC

11/11/2018
/ Publications
/
IMPT
Immunotherapy

A review on PBT for NSCLC. The review pointed out that despite early results suggesting improvements or at least comparable outcomes, the most recent randomized...

Patterns of Local-Regional Failure after IMRT or Passive Scattering PT with Concurrent Chemotherapy for NSCLC.

08/08/2018
/ Publications
/
IMPT

Published in the Red Journal, this retrospective analysis by MD Anderson group reviewed 212 patients treated with IMRT and PT, most (152 [72%]) had no failure...

Advanced radiation techniques for locally advanced NSCLC: IMRT and proton therapy.

08/08/2018
/ Publications
/
IMPT
IMRT

This review article examined clinical outcomes data of IMRT and PBT for locally advanced NSCLC. This review pointed out that PBT is not considered the standard...

Reirradiation for locoregionally recurrent non-small cell lung cancer.

08/08/2018
/ Publications
/
Reirradiation
IMPT
Survival

In the context of definitive retreatment, increasing reRT dose can potentially improve OS and offer a chance of cure, particularly in patients with limited loco...

Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma (EC).

11/06/2017
/ Publications
/
IMPT
Chemotherapy
Toxicity

19 patients with EC treated with IMPT concurrently with chemotherapy. Clinical complete response was achieved in 84%.

The most common grade 3 acute toxicities...

High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.

15/11/2022
/ Publications
/
IMPT
IMRT

This is a study protocol details a randomized trial taking place in Thailand with multiple centers comparing IMPT and IMRT for stage II–IVA squamous thoracic...

Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.

15/11/2022
/ Publications
/
IMPT
IMRT

163 consecutively treated patients with biopsy-proven, stage III NSCLC who received IMPT (n = 35, 21%) or IMRT (n = 128, 79%) were analyzed in this study...